Returns At Britannia Life Sciences (CSE:BLAB) Appear To Be Weighed Down

There are a few key trends to look for if we want to identify the next multi-bagger. Amongst other things, we'll want to see two things; firstly, a growing return on capital employed (ROCE) and secondly, an expansion in the company's amount of capital employed. This shows us that it's a compounding machine, able to continually reinvest its earnings back into the business and generate higher returns. Although, when we looked at Britannia Life Sciences (CSE:BLAB), it didn't seem to tick all of these boxes.

Return On Capital Employed (ROCE): What Is It?

Just to clarify if you're unsure, ROCE is a metric for evaluating how much pre-tax income (in percentage terms) a company earns on the capital invested in its business. Analysts use this formula to calculate it for Britannia Life Sciences:

Return on Capital Employed = Earnings Before Interest and Tax (EBIT) ÷ (Total Assets - Current Liabilities)

0.0075 = CA$137k ÷ (CA$23m - CA$4.7m) (Based on the trailing twelve months to December 2022).

Thus, Britannia Life Sciences has an ROCE of 0.8%. In absolute terms, that's a low return and it also under-performs the Professional Services industry average of 12%.

Check out our latest analysis for Britannia Life Sciences

Historical performance is a great place to start when researching a stock so above you can see the gauge for Britannia Life Sciences' ROCE against it's prior returns. If you'd like to look at how Britannia Life Sciences has performed in the past in other metrics, you can view this free graph of past earnings, revenue and cash flow.

So How Is Britannia Life Sciences' ROCE Trending?

There are better returns on capital out there than what we're seeing at Britannia Life Sciences. The company has employed 115% more capital in the last two years, and the returns on that capital have remained stable at 0.8%. This poor ROCE doesn't inspire confidence right now, and with the increase in capital employed, it's evident that the business isn't deploying the funds into high return investments.

On a side note, Britannia Life Sciences has done well to reduce current liabilities to 21% of total assets over the last two years. Effectively suppliers now fund less of the business, which can lower some elements of risk.

In Conclusion...

Long story short, while Britannia Life Sciences has been reinvesting its capital, the returns that it's generating haven't increased. Since the stock has declined 32% over the last year, investors may not be too optimistic on this trend improving either. Therefore based on the analysis done in this article, we don't think Britannia Life Sciences has the makings of a multi-bagger.

Since virtually every company faces some risks, it's worth knowing what they are, and we've spotted 4 warning signs for Britannia Life Sciences (of which 2 don't sit too well with us!) that you should know about.

While Britannia Life Sciences isn't earning the highest return, check out this free list of companies that are earning high returns on equity with solid balance sheets.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.